Memic has set out to transform robot-assisted surgery, with proprietary technology that has the potential to far surpasses today’s best solutions. Providing unprecedented access and maneuverability, our Memic’s Hominis™ surgical platform features miniature, humanoid-shaped robotic arms with human dexterity, superhuman flexibility, and 360˚ articulation for various access configurations. Dramatically smaller, more versatile, and less costly than current robotic platforms, our technology opens up a host of minimally -invasive procedures that until now have been off-limits to robot-assisted surgery. Some pipeline indications include abdominal single and multi-port surgery, as well as procedures performed in a trans-oral approach. We envision a near future where numerous indications – and millions of patients – will benefit from these disruptive capabilities.

our people
  • Dvir Cohen Chief Executive Officer

    Dvir Cohen has served as our Chief Executive Officer since October 2013.strong>
    Mr. Cohen has been a leader in the Company from its inception and also serves as a president of our U.S. subsidiary, Memic Innovative Surgery Inc. Mr. Cohen brings more than fifteen (15) years of experience in innovative robotic systems. Prior to joining the Company, Mr. Cohen served in various positions in the Israeli Ministry of Defense as an awarded officer specializing in robotic systems for various applications. From 2011 to 2013, Mr. Cohen held the positions of research and development manager and robotic project specialist in an elite technology unit of the Israel Intelligence Force. From 2007 to 2011, Mr. Cohen led several opto-mechanical disruptive solutions in the Ministry of Defense, one of which won the Israel Defense Award. Mr. Cohen has experience at all stages of product development, from the early conceptual stage through prototyping to production line implementation and final market. Mr. Cohen earned an M.B.A in 2013 from the Recanati Business School at Tel Aviv University with a major in Business Strategy and Entrepreneurship. He also earned B.Sc. and M.Sc. degrees in Mechanical Engineering from the Technion as part of the “Brakim” excellence program in 2007.

    Hagai BerkovichChief Operations Officer

    Hagai Berkovich leads our operations department and has done so since October 2018.
    In his last role before joining the Company, from January 2017 to October 2018, he served as Supply Chain Director at Check-Cap, a medical device company developing the world’s first ingestible imaging capsule system for colorectal cancer screening. Mr. Berkovich has over twenty-four (24) years of executive, leadership and management experience in operations. From 2015 to 2017, he served as COO at Motorika, a robotic company for rehabilitation solutions, and he served as Operations VP and CEO at Tamuz F.T.K Solutions from 2011 to 2015, where he led the scale up activities with respect to the Mazor robotic system. His other roles have included Operations, Airborne Structure Director at Elbit Systems – Cyclone from 2009 to 2011 and Business Unit Vice President at Sanmina SCI – Israel Medical Systems from 2003 to 2009. Mr. Berkovich holds an M.B.A. from the Recanati Business School at Tel-Aviv University and a B.Sc. in Aeronautical Engineering from the Technion.

    Noam AtarChief Financial Officer

    Noam Atar has served as our Chief Financial Officer since January 2020. Mr.
    Atar also serves as the secretary and treasurer of our U.S. subsidiary Memic Innovative Surgery Inc. Mr. Atar brings over twenty (20) years of experience as a finance and operations executive with a strong track record formulating and executing strategic initiatives across business operations and changing management, conceptualizing and leading on multi-functional process and performance transformations, generating consensus through collaboration and organizational alignment, and introducing innovation to achieve financial and business goals. Prior to joining the Company, Mr. Atar served as Senior Director of Finance & Supply Chain at Ferring Pharmaceuticals from 2015 to 2019 where he led company-wide strategic and operational initiatives. From 2009 to 2015, Mr. Atar served as controller of Bio Technology General Ltd and from 2007 to 2009 as the controller of international operations of Radware (RDWR). Prior to that from 2004 to 2007 Mr. Atar served as a senior auditor at PWC. Mr. Atar was also the co-founder & CEO of Rway Applications. Mr. Atar is a certified public accountant. He holds a Bachelor of Accounting and Economics from the Hebrew University and an M.B.A. from the Recanati Business School at Tel Aviv University. In addition, Mr. Atar is certified in Business Analytics by Harvard Business School Online.

    Limor KuznitzVice President of Clinical Affairs

    Limor Kuznits serves as the Company’s Vice President of Clinical Affairs since June 2019.
    She led the clinical development of the Company’s product and established the post-market study to support the Company’s soft launch. Ms. Kuznits served as a Clinical Trial Manager at BlueWind Medical from 2014 to 2019, as a Clinical Research Associate at Gardia Medical from 2012 to 2014 and as a Clinical Research Associate at IceCure Medical from 2011 to 2012. She holds a B.Sc. in Biomedical Engineering from Tel Aviv University and is certified as a Clinical Research Associate for monitoring and coordinating clinical trials by Bioforum Ltd.

    Dr. Yaron Levinson Vice President of Research and Development

    Yaron Levinson has been the Company’s Vice President of Research and Development since 2015.
    He led the development of the Hominis® Surgical System from the technological incubator to a fully operating surgical system. Dr. Levinson was the CEO and founder of Paragon Measure Inc., a digital health company leveraging machine learning algorithms in passive telemonitoring of patients from 2013 to 2015. From 2009 to 2013, Dr. Levinson served as System and Control Manager at Medical Surgery Technologies (MST) where he led the motion control development of the AutoLap robotic surgical system from the prototype stage to FDA and CE clearance. Dr. Levinson earned a B.Sc. and an M.Sc. in Mechanical Engineering from Ben Gurion University of the Negev and a Ph.D. in Control Theory Signal Processing and Optimization from the Technion. He also completed the Runway Start-up Post-Doctorate Program in Mobile Health and Machine Learning at Jacobs-Technion Cornell Institute.

    Steven NunesChief Commercial Officer

    Mr. Nunes has been the Company’s Chief Commercial Officer since September 2019 and serves as the Chief Commercial Officer of our U.S. subsidiary, Memic Innovative Surgery Inc.
    He is a highly accomplished senior executive with thirty five plus (35+) years of experience leading the commercialization of innovative technologies for less invasive surgery. He has a career record of success in medical device startup companies, turnaround situations, and market expansion with large market-leading companies. Prior to joining the Company, Mr. Nunes was a founding member and Senior Vice President of Sales and Marketing of Mako Surgical, where he was part of a team that led unusually strong revenue growth, taking the company from inception to more than $85 million in revenue in four (4) years. Mako Surgical’s success in the orthopedic joint replacement market led to its acquisition by Stryker for $1.7 billion. Prior to joining Mako, Mr. Nunes was retained as a senior sales and marketing executive by GE Healthcare following its acquisition of Visualization Technology, Inc. (VTI), an early market leader in development and sales of electromagnetic based image guided surgery systems. Mr. Nunes was responsible for the commercialization of VTI’s products from inception, established the VTI’s products as standard of care in the market and led the integration of VTI’s commercial organization into GE Healthcare. From 1990 to 1996, Mr. Nunes served as a distributor for Richard Wolf Medical Instruments, a pioneer in products for laparoscopic surgery and a market leader and innovator in gynecologic surgery. Mr. Nunes received a BA in Communications from University of Massachusetts Amherst.

    Sheryl SabbanVice President of Intellectual Property

    Sheryl Sabban leads the Company’s intellectual property department and manages our IP portfolio and strategy.
    Ms. Sabban has been with the Company since 2019. Ms. Sabban is a licensed Israeli patent attorney with extensive experience of over fifteen (15) years building valuable intellectual property portfolios and strategic intellectual support in both early stage and global companies. Prior to joining Memic, Ms. Sabban served from April 2018 to March 2019 as the IP manager of Curesponse & Aummune, an early stage company in the area of diagnostics and precision oncology. From November 2006 to April 2018, Ms. Sabban was a member of Teva Pharmaceutical Industries Ltd.’s (“Teva”) IP team where she served as IP director in the Specialty and Innovative Division which focused on innovative medical technologies and as Senior Patent Manager of the group responsible for designing global strategy for U.S. commercialization in Teva’s Generic Division. She holds a B.Sc. in Biology and an M.Sc. in Medical Science from the Hebrew University.

    Einav Yemini Vice President of Quality Assurance and Regulatory Affairs

    Ms. Yemeni, as Vice President of Quality Assurance and Regulatory Affairs, leads the Company’s regulatory department.
    Ms. Yemeni joined the Company in 2016. Previously, from 2013 to 2016, she served as regulatory associate at Intuitive Surgical. Ms. Yemeni brings extensive experience with single-port robotic instruments and multiple submissions of 510(k) files to the FDA. Between 2011 and 2013, Ms. Yemeni served as RA, Design and Specification engineer at IVT Medical and as a research assistant at the Neurogenomics Lab at Sheba Medical Center. She holds a B.Sc. in Biomedical Engineering from Tel Aviv University.

  • Maurice Ferre Chairman of the Board

    Maurice R. Ferré MD is INSIGHTEC’S CEO and chairman of the board of directors. He brings over 20 years of experience in the medical device industry. Before INSIGHTEC, Dr. Ferré served as chairman of the board and CEO of MAKO Surgical Corp., a transformational robotic surgical company that he co-founded in 2004. The company was IPO’d in 2008 and sold to Stryker Corp. for $1.65 billion in 2013. Prior to MAKO, Dr. Ferré was founder, CEO, and president of Visualization Technology, Inc., which became the world leader in image-guided surgery for ENT, cranial, and orthopedic procedures. The company was acquired by GE Healthcare in 2002.
    Dr. Ferré earned his Doctor of Medicine and Master of Public Health degress from Boston University. He received the prestigious Ernest & Young 2007 Entrepreneur of the Year Award. He is currently active on the boards of Advamed, the Everglades Foundation, and Boston University.

    About INSIGHTEC: the company’s MR-guided focused ultrasound technology allows to perform procedures with surgical precision but without incisions, thus transforming the standard of care. The company’s non-invasive Exablate and Exablate Neuro platforms are clinically proven for treating essential tremor, painful bone metastases, and uterine fibroids. INSIGHTEC continuously invests in and expanding its current and investigational applications.

    Eyal Lifschitz Chairman of Board's Business Committee

    Eyal Lifschitz is CEO, general partner, and co-founder of Peregrine Ventures.
    Prior to founding Peregrine, Eyal co-founded and led the business development efforts of multiple medical technology companies, including PharmaSys (acquired by Elan Corp. NYSE:ELN), ECR (acquired by AVX Corp. NYSE:AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. From 2003-2007, Eyal also served as a director of Given Imaging (NASDAQ: GIVN).

    Peregrine is an Israeli venture capital fund, with a focus on medical devices and an impressive record of founding, managing, and promoting Israeli hi-tech companies. Peregrine enjoys a wide network of contacts, and is supported by a investment committee and advisory board consisting of expert teams specializing in all applicable disciplines. The fund has invested in and initiated some of Israel’s leading medical companies, including Neovasc, B-Balloon, Valtech, Eximo, Memic, and Cordio.

    Lior Shahory Board Member

    Lior brings extensive experience in investment due diligence, strategic planning, project management, and business development. He works closely with entrepreneurs to establish successful companies.
    Lior serves as CEO of Incentive, Peregrine’s technology incubator. Under his leadership, Incentive has received seven excellence awards from the State of Israel.
    Prior to Peregrine, Lior served as deputy director of the Israel Chief Scientist’s incubator program.
    Lior holds a BA in economics and business management from the University of Haifa, and an MBA from Tel Aviv University.

    Dr. Irit Yaniv M.D., MBA Board Member

    Dr. Irit Yaniv is a seasoned medtech executive, and has held CEO positions at medical device companies Impulse Dynamics and MetaCure.
    Dr. Yaniv plays a key role in leading Accelmed’s early-stage portfolio companies, serving either as chairperson or as an active board member.
    Dr. Yaniv holds an MD degree from Ben Gurion University, and an MBA from the Recanati Business School at Tel Aviv University.

    Accelmed is an investment firm focused on creating value for medical device companies and technologies. Founded by Mori Arkin and Uri Geiger. It invests in small and mid-cap private and public companies. A successful advocate of the platform model with a proven track record, Accelmed boasts a large team of accomplished investment professionals. Its vision is to create leading med-tech players by merging commercial platforms with small innovative growth companies, predominantly from Israel.

    Yigal Cohen Orgad Board Member

    Mr. Cohen-Orgad has served as Israel’s Minister of Finance, as a director of Bezeq Israel Telecommunication Corp., and as a director of Israel Electric Corporation. He is Chancellor of Ariel University, and sits on the board of Ariel University’s R&D company.

    Ariel Scientific Innovations is a leading technology transfer company committed to transforming Ariel University (AU) technologies into products with a positive impact on society.
    Ariel Scientific Innovations acts as a professional partner to AU researchers, by identifying innovations, patenting inventions, supporting applied research, and commercializing the results to selected commercial partners.

    Dr. Israel Frieder Board Member

    Dr. Israel Frieder serves Ltd., as chairman at AA Pearl Investments, Ltd., as chairman at ETV Energy, Ltd., and as chairman at Ariel Scientific Innovations Ltd.
    He has served on the board of directors at RR Media, at Cellvine Ltd., and at RiT Technologies Ltd.
    He received his graduate degree from the Technion, an MBA from the Hebrew University of Jerusalem, and a doctorate degree from Bar-Ilan University.

    Dr. Morry Blumenfeld Board Observer

    Dr. Morry Blumenfeld is president and CEO of medical device consulting company Quescon Consultants, Ltd., and a partner at Meditech Advisors, LLC. He was an executive at GE for nearly 35 years, and served GE Medical Systems Business in numerous roles, including initiating both the CT and MRI businesses, and as managing director of GE Medical Systems in Israel.
    Morry holds five patents, and serves or has served on the boards of a number of medical device and technology companies in the USA and Israel – as well as numerous Canadian, international, and Israeli advisory boards in technology and science. He is on the board of the Hebrew University and Yissum (the Hebrew University’s tech transfer company), and on the scientific advisory board of the Momentum Fund of Ramot (Tel Aviv University’s tech transfer company).
    Dr. Blumenfeld received his undergraduate degree and Ph.D from the University of Toronto.

    Guy ShamirBoard Observer

    Mr. Guy Shamir has served as business development manager at Mivtach Shamir Holdings, Ltd. since 2011.
    He previously served as a director at Tefron, Ltd., and as a director at Manif Financial Services, Ltd.
    He holds a degree in business administration from the Interdisciplinary Center in Herzliya.

    Mivtach Shamir Holdings is an investment company based in Israel, led by Israeli investor Meir Shamir. Mivtach Shamir invests in three sectors: technology and communications, industrial investments, and real estate. Shares of Mivtach Shamir are traded on the Tel Aviv Stock Exchange (TASE: MISH).

back to top
think nimble

think nimble

think boundless

think boundless

clinical spectrum
think forward

think forward

news & events
think together

think together

contact us